SCHEMBL22494446

SCHEMBL22494446

CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)nc(N)nc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MTOR P42345 20/20 1.00
RICTOR Q6R327 15/20 1.00
RPTOR Q8N122 15/20 1.00
MAPKAP1 Q9BPZ7 15/20 1.00
MLST8 Q9BVC4 15/20 1.00
PIK3CA P42336 10/20 1.00
PIK3CD O00329 1/20 0.77
PIK3CB P42338 1/20 0.77
PIK3CG P48736 1/20 0.77
PIK3C3 Q8NEB9 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7894978 0.90 MTOR (0.82) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL22494381 0.89 MTOR (1.00) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL30382528 0.89 MTOR (1.00) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL22494262 0.89 MTOR (1.00) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL22494261 0.89 MTOR (1.00) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL22494311 0.87 MTOR (0.77) MTORRICTORRPTORMAPKAP1MLST8
Sapanisertib SCHEMBL7902875 0.87 MTOR (1.00) MTORRICTORRPTORMAPKAP1MLST8
Sapanisertib SCHEMBL29351459 0.87 MTOR (1.00) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL26093528 0.86 MTOR (0.75) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL25106888 0.85 MTOR (0.82) MTORRICTORRPTORMAPKAP1MLST8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731973-B2 Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors GALDERMA RESEARCH & DEVELOPMENT (FR) 2023-08-22 US claimed
EP-3727389-B1 COMPOUNDS AS MTOR INHIBITORS GALDERMA RES & DEV (FR) 2023-05-03 EP claimed
US-11731973-B2 Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors GALDERMA RESEARCH & DEVELOPMENT (FR) 2023-08-22 US disclosed
US-11731973-B2 Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors GALDERMA RESEARCH & DEVELOPMENT (FR) 2023-08-22 US disclosed
US-11731973-B2 Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors GALDERMA RESEARCH & DEVELOPMENT (FR) 2023-08-22 US disclosed
EP-3727389-B1 COMPOUNDS AS MTOR INHIBITORS GALDERMA RES & DEV (FR) 2023-05-03 EP disclosed
EP-3727389-B1 COMPOUNDS AS MTOR INHIBITORS GALDERMA RES & DEV (FR) 2023-05-03 EP disclosed
CN-111918653-A Novel MTOR inhibitor compounds 盖尔德马研究及发展公司 2020-11-10 CN disclosed
EP-3727389-A1 NOVEL MTOR INHIBITOR COMPOUNDS Galderma Research & Development (FR) 2020-10-28 EP disclosed
US-20200317679-A1 NOVEL MTOR INHIBITOR COMPOUNDS GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-10-08 US disclosed
US-20200317679-A1 NOVEL MTOR INHIBITOR COMPOUNDS GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317679-A1 NOVEL MTOR INHIBITOR COMPOUNDS MTOR, RICTOR, RPTOR MTOR 1/4885RICTOR 2/4885RPTOR 3/4885
US-11731973-B2 Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors MTOR, RICTOR, RPTOR MTOR 1/4885RICTOR 2/4885RPTOR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.